

Lian Sheng Ma,
Science Editor, Company Editor in Chief
Baishideng Publishing Group Inc

Dr Dr Sheng Ma,

Re: NO: 61435 : Are nucleotide inhibitors a potential option for the treatment of COVID 19 compared with standard of care? A literature review.

Further to your message dated January, 27th 2021, I am hereby resubmitting the invited, above-mentioned review for publication in World Journal of Virology.

The manuscript has been revised and edited according to reviewers comments.

I addressed the points raised by the reviewers (see item-by-item response) and revised the text accordingly.

As the Science Editor Jin Lei Wang suggested,
the key word “HCV” has been added to the title;
The author contributions have been provided;
PMID and DOI of references 3, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 33, 34, 35, 36, 37, 39, 40, 41 are correctly and properly cited.

All reported references are relevant to the present study.

Looking forward to hearing from you,

Yours sincerely,

Anna Maria Spera, MD
ORCID 0000-0003-1292-3040

Reply to reviewer 04229132

There is just one ortographic mistake in table 1. I suggest to write "may determine" instead of "may determines".

Authors' reply. Ortographic mistakes have been corrected in Table 1

Reply to reviewer 05427747

A great deal of language polishing

Authors' reply. A language editing certificate issued by SNAS has been provided